16.80

2.07% -0.3484

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $16.80, with a volume of 622.10K. It is down -2.07% in the last 24 hours and up +51.44% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Previous Close:

$17.15

Open:

$17.12

24h Volume:

622.10K

Relative Volume:

0.44

Market Cap:

$1.29B

Revenue:

$54.55M

Net Income/Loss:

$-193.57M

P/E Ratio:

-5.8137

EPS:

-2.89

Net Cash Flow:

$-181.86M

1W Performance:

+32.45%

1M Performance:

+51.44%

6M Performance:

+72.79%

1Y Performance:

-23.03%

1-Day Range:

$16.75

$17.54

1-Week Range:

$12.61

$17.65

52-Week Range:

$8.18

$23.00

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1138)

Industry

Biotechnology (635)

Phone

(415) 660-5320

Address

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Employee

286

Twitter

Next Earnings Date

2025-10-09

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	16.78	1.74B	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	429.20	107.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	781.88	80.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	431.18	57.37B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	908.04	55.83B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	207.44	44.13B	447.02M	-1.18B	-906.14M	-6.1812

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Resumed	Truist	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

11:31 AM

Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at Truist Financial - MarketBeat

11:31 AM

07:19 AM

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times

07:19 AM

07:00 AM

Nurix Therapeutics (Nasdaq: NRIX) fireside chat at Piper Sandler 37th conference - Stock Titan

07:00 AM

Nov 24, 2025

Truist Securities Raises Price Target for Nurix Therapeutics (NR - GuruFocus

Nov 24, 2025

Nov 22, 2025